image: Images showing the movement of the glucose regulator GK (green) in the nucleus in the presence or absence of the new treatment TTP399. This new diabetes treatment activates GK to lower glucose levels.. This material relates to a paper that appeared in the Jan. 16, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by A. Vella at Mayo Clinic in Rochester, Minn.; and colleagues was titled, "Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator." view more
Credit: A. Vella <i>et al., Science Translational Medicine </i> (2018)